Clinical Trial Detail

NCT ID NCT02846766
Title Study of Lenvatinib in Patients With Advanced Cancer and Aberrations in FGF/FGFR Signaling
Recruitment Withdrawn
Gender both
Phase Phase II
Variant Requirements Yes
Sponsors Teresa Helsten, MD
Indications

Advanced Solid Tumor

Therapies

Lenvatinib

Age Groups: adult senior

Additional content available in CKB BOOST